
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is viewed positively because its legacy multiple sclerosis franchise remains a durable cash engine, while a diversified growth portfolio is increasingly offsetting decline and reducing loss-of-exclusivity risk. In 3Q26, revenues were about $2.8B, up 10.6% year over year, with non-GAAP EPS of $2.62 beating estimates and the growth portfolio contributing 63% of core pharmaceutical revenue, underscoring improving mix and operating resilience. The outlook is further supported by meaningful near-term catalysts across immunology and rare disease, including late-stage litifilimab, felzartamab, and zorevunersen readouts, plus strong momentum from Spinraza, Skyclarys, Leqembi, Syfovre, and Empaveli.
Bears say
Biogen is facing a structurally weakening core business, as its multiple sclerosis franchise remains the largest revenue generator yet is in decline and still accounted for 40% of total revenue in 2025. Its next-wave growth assets have yet to offset that pressure, with Leqembi, Skyclarys, and Zurzuvae all vulnerable to slower-than-expected sales ramps, while the CD20 collaboration with Roche, which contributed 19% of total revenue in 2025, also exposes the company to partner-driven and competitive dynamics. The bearish view is reinforced by the risk of ongoing clinical setbacks across programs such as SLE, CLE, AMR, and DS, alongside competitive pressure from LLY’s donanemab.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Biogen (BIIB) Forecast
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares